"MONMOUTH JUNCTION, NJ--(Marketwired - Jul 8, 2013) - Insmed Incorporated (NASDAQ: INSM), ("Insmed" or the "Company"), a biopharmaceutical company focused on developing and commercializing an inhaled anti-infective to treat patients battling serious lung diseases that are often life-threatening, today announced that Will Lewis, President and Chief Executive Officer of Insmed, will be presenting a corporate overview at the 8th Annual JMP Securities Healthcare Conference on Wednesday, July 10th at 11:00 a.m. Eastern time at The St. Regis New York."
New Slide Presentation for JPM conference available in Insmed Company website showing CF results, NTM updates, 11.5 million from Shire (25) , supplied drugs second site 200L 1H 2014, and much more ... very informative and great slide set.
Ooo, this'll be great! I can't wait to see what will has to say to JP Morgan, eh fud?
Seriously, there does seem to be some optimism, with the SP climbing over 3% this morning.
We could use some truly good news, particularly a definitive and clear message factually assuaging side effect concerns.
Are you overlooking the fact that the number of subjects with serious adverse events was greater in the Tobi arm (29 vs. 26) and that the only life-threatening or disabling adverse event occurred in the Tobi arm?
I hope somebody asks for guidance on the anticipated timing of the next share offering.
And in the hope of sparing others here from the otherwise-predictable pathetic attempts at point-scoring by the more incomplete of our species who use this forum - I'm not so motivated to have that uncertainty resolved that I'm prepared to suffer the expense of phoning in from where I live.